
HydraMed Review
HydraMed is no longer available as we reviewed it, so this page is kept for reference.
HydraMed: Website is offline and is not taking patients. We're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
See our top-rated GLP-1 providers →HydraMed was a telehealth platform that sold compounded semaglutide and tirzepatide, plus a wider peptide menu and mobile IV services, in about a dozen states. Its website stopped working in mid-2026 and the address now shows a parked-domain page, so there is no way to sign up, refill or check prices.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Vetted alternatives to HydraMed
Ro
Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Editorial score · methodology
Collective
Best for: the lowest flat medication price if you can absorb an annual membership fee
Editorial score · methodology
CoreAge Rx
Best for: lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Editorial score · methodology

HydraMed at a glance
- Type
- GLP-1 telehealth provider
- Availability
- 11 states
- FDA status
- 1 FDA warning letter on record; see below
How we scored HydraMed
Each dimension is scored algorithmically from HydraMed’s published pricing, drugs offered, verification status, and disclosed inclusions, using the same six-dimension framework we apply to every provider.
Value25%
6.6/10HydraMed no longer sells GLP-1 treatment, so no current price applies.
Effectiveness25%
6.0/10HydraMed's offering is not built around the GLP-1 molecules with the strongest weight-loss trial evidence, so weigh the clinical support carefully.
User Experience15%
7.4/10Online intake and platform experience; 2 platform features disclosed.
Trust & Safety15%
6.3/10Key details fully confirmed by our editors; an FDA warning letter is on file (see flag above).
Accessibility10%
7.0/10HydraMed is available in 11 states. Confirm yours is covered.
Support10%
6.4/10HydraMed provides standard clinician follow-up; no extended coaching or community program is disclosed.
Each checked against the provider’s own site.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this HydraMed review
Last checked August 2026- Confirmed availability in 11 states
- Checked the FDA warning-letter database for enforcement actions
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records. See the sources below. Editorial confidence in this data: high.
What we checked
- FDA warning-letter register
- An active letter is on file for this provider; see below
What we like
- Review page kept live so former patients get a straight answer
Watch-outs
- Website is offline, so there is no way to sign up or reorder
- Received an FDA warning letter in June 2026 about the compounded semaglutide and tirzepatide on its website
HydraMed's website is offline and it is not taking patients
If you came here looking for HydraMed's compounded semaglutide and tirzepatide program, there is nothing left to sign up for. HydraMed's website started returning a server error page in mid-2026, and the address now shows a parked-domain placeholder with no HydraMed content at all: no prices, no intake and no way to reorder.
When it was running, HydraMed sold compounded GLP-1s bundled with the consult, supplies and shipping, alongside a wider peptide menu and mobile IV services, in about a dozen states. HydraMed has published no closure notice and no new address, so we treat it as closed until it comes back with a working site.
What to do if you were a patient
Talk with a prescriber before your current supply runs out. A GLP-1 dose should be continued or adjusted on clinical advice, not interrupted because a provider went offline, and restarting at a high dose after a gap can be unsafe. If your medication label names a pharmacy, keep that information handy, because the dispensing pharmacy is a separate business from the platform that arranged your visits.
Before you move your care, note that in June 2026 the FDA sent HydraMed a warning letter about the compounded semaglutide and tirzepatide offered on its website. Our FDA warning letter tracker lists it alongside letters sent to other telehealth sellers.
Where to look instead
The alternatives listed on this page are all currently operating and carry current prices. You can also start from our semaglutide provider rankings and compare what each provider includes as well as what it charges, using the factors in our scoring methodology.
Bottom line
HydraMed is no longer reachable online and is not taking patients. We keep this page up so people searching for HydraMed get a clear answer rather than a dead link. It is excluded from our rankings and carries no outbound link.
The Bottom Line
HydraMed is no longer available as we reviewed it, so this page is kept for reference.
HydraMed might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
- If you want brand-name Ozempic, Wegovy, Mounjaro or Zepbound, consider altRX.
- If you want built-in coaching and behavior-change support, consider Ro.
- If you live outside its coverage area and need nationwide access, consider CoreAge Rx.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
HydraMed received an FDA warning letter dated June 8, 2026
The letter concerns false & misleading claims/misbranded (telehealth). FDA warning letters are public regulatory communications and do not, on their own, constitute a finding of illegal activity. Companies often respond with corrective action.
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this HydraMed review:
Sources & methodology (as of November 2026)
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.